Abstract
Objective
Kawasaki disease (KD) can lead to permanent damage to coronary structures, the pathogenesis of which remains unknown. This experiment was designed to investigate whether miR‐223‐3p secreted in the serum of KD patients affects the proliferation and apoptosis of HCAECs in KD by regulating FOXP3.
Methods
Blood samples were collected in acute febrile phase of KD, after IVIG treatment, and from healthy controls. Transfected into HCAECs cells by synthetic FOXP3 siRNA/NC. A co‐culture system was established between HCAECs cells transfected with FOXP3 siRNA/NC and THP1 cells added with three sera.
Results
Compared with the control group, the expressions of miR‐223‐3p, RORγt, and Th17 in serum of KD patients were significantly upregulated, and the expressions of TGF‐β1, FOXP3 and Treg were significantly downregulated. At the same time, the levels of IL‐6, IL‐17, and IL‐23 were significantly increased, and the levels of IL‐10 and FOXP3 were significantly decreased. After IVIG treatment, the patient's above results were reversed. The serum of KD patients increased the expression of miR‐223‐3p and inhibited the expression of FOXP3 in HCAECs cells. IVIG serum is the opposite. Overexpression of miR‐223‐3p also promoted the apoptosis of HCAECs. In addition, serum from KD patients promoted apoptosis, whereas serum after IVIG treatment inhibited apoptosis. KD patient serum downregulated the expression of FOXP3, Bcl2, TGF‐β1 and IL‐10 in cells, and upregulated the expression of caspase3, Bax, IL‐17, IL‐6, and IL‐23. The opposite results were obtained with IVIG‐treated sera.
Conclusion
miR‐223‐3p secreted in serum of KD patients can regulate the expression of FOXP3 and affect the proliferation, apoptosis, and inflammation of cells.
Keywords: apoptosis, FOXP3, inflammation levels, Kawasaki disease, miR‐223‐3p
It was verified that Kawasaki disease (KD) serum has high level of miR‐223‐3p and low level of FOXP3. A co‐culture system was established with HCAECs cells and THP1 cells treated with three serum samples. It was verified that serum miR‐223‐3p in KD patients may affect cell proliferation, apoptosis, the expression of inflammatory cytokines, and the level of angiogenesis factors by regulating FOXP3.

1. INTRODUCTION
Vascular injury is the leading cause of morbidity and mortality in Kawasaki disease (KD), 1 , 2 also a major reason for heart disease in children worldwide. 3 Diagnosis is mainly based on the clinical features including fever lasting 5 days or more with the presence of bilateral conjunctival injections, oral changes, cervical lymphadenopathy, extremity changes, and a pleomorphic rash. 4 KD can be treated with intravenous immunoglobulin (IVIG), oral aspirin, or anti‐inflammatory agents such as TNF‐α blockers and IL‐1 receptor antagonist. 5 , 6 , 7 Particularly, early and proper use of IVIG is very important for preventing cardiovascular complications. 8
miRNAs can participate in various biological processes such as cell apoptosis, angiogenesis, and differentiation. 9 , 10 miR‐223 is a blood‐forming lineage miRNA that is exported in cells such as blood platelets and leukocytes of the bone marrow. 11 Chen et al. 12 confirmed the upregulation of hsa‐miR‐223‐3p in the plasma of acute KD patients by microarray gene chip, and speculated that it is involved in the pathogenesis of KD. Clinical studies have shown that in the diseased state of KD, blood cells are excited and release more miRNAs into the serum, leading to a rise in the levels of miRNAs, such as miR‐223, in vascular wall ECs and vascular smooth muscle cells (VSMCs). Increased miR‐223 in vascular cells from KD patients increases vascular cell damage, ultimately leading to vascular damage, such as vascular thrombosis and aneurysm. 13 Therefore, miR‐223‐3p is an essential regulator of intracellular damage in KD.
Imbalance of Th17/Th1 and Th2/Treg affects the progression of KD, with increased Th17/Th1 responses, increased levels of IL‐6, IL‐10, IL‐17A, IFN‐γ, and IP‐10, decreased Th2/Treg responses, and decreased IL‐6, IL‐10, IL‐17A, IFN‐γ, and IP‐10 levels ‐4. Decreased expression of IL‐5, FoxP3, and TGF‐β. 14 Forkhead Box P3 (FOXP3) is mainly expressed in the T regulatory cell (Treg) subpopulation in CD4+ cells, and is the most important marker of this cell subtype and is involved in the activation of Treg cells. 15 Whether miR‐223 secreted in serum of KD patients can regulate the apoptosis of coronary endothelial cells by regulating FOXP3, and then participate in the progression of KD, has not been reported yet. Therefore, this experiment was to assess the effect of FOXP3 interference on HCAECs cells by collecting blood samples from the acute phase of KD, after IVIG treatment and healthy controls. To evaluate the regulatory effect of serum miR‐223‐3p in KD patients on FOXP3 in HCAECs cells, and its effects on cell apoptosis, inflammasome, inflammatory cytokine expression, and angiogenesis factors.
2. MATERIALS AND METHODS
2.1. Main reagent
Trizol (15596026; Ambion). All ELISA kits were purchased from Bioswamp. All antibodies were from bioswamp. Opti‐MEM (31985‐062; Gibco). Lipofectamine® RNAiMAX (13778030; Invitrogen). MTT (M1025; Solarbio). DMSO (D2650; SIGMA). Annexin V‐FITC/PI Apoptosis Detection Kit (556547; BD).
2.2. Clinical sample testing
From August 2021 to October 2022, 15 children with KD were randomly selected as the KD group (age: 33.3 ± 24.6 months), 15 healthy children were randomly selected as the control group (age: 38.5 ± 38.4 months), children in the IVIG group were KD children after IVIG treatment. Collect serum from children in the acute phase of KD, post‐IVIG KD serum (2 g/kg IVIG treatment) and health serum (similar age, healthy, without any infection, or inflammation). Blood collection by vein.
2.3. Cell culture
HCAECs cells were derived from Shanghai Saibaikang. Thp‐1 cells were obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences. Move the cells to a 37°C water bath. After completely thawing, pipette the cell suspension into a centrifuge tube, add 4 mL of complete medium, then centrifugation is performed. Incubate in a 37°C, 5% CO2 incubator. Divide cells into four groups: Normal group: HCAECs cells, cultured normally; Control group: HCAECs cells + health serum; KD group: HCAECs cells + KD serum; IVIG group: HCAECs cells + post‐IVIG KD serum.
2.4. qRT‐PCR
Take the cell samples into a 1 mL Trizol homogenization tube for total RNA extraction. RNA is then reverse‐transcribed into cDNA. PCR amplification of the prepared cDNA. The reaction program was: predenaturation at 95°C for 3 min; 95°C for 5 s, 56°C for 10 s, and 72°C for 25 s (40 cycles). The relative content of mRNA was calculated using . PCR primers are shown in Table 1.
Table 1.
Primer sequence.
| Primer name | Sequence | Size (bp) |
|---|---|---|
| TGF‐β1‐F | TGTGGCTACTGGTGCTGAC | 275 |
| TGF‐β1‐R | CTCCTTGGCGTAGTAGTCG | |
| RORγt‐F | GCTGACCCCTGACCGAT | 184 |
| RORγt‐R | TGTCTCCCTGTAGGACTTGC | |
| FOXP3‐F | GCTGGCAAATGGTGTCTG | 258 |
| FOXP3‐R | GAGCCCTTGTCGGATGAT | |
| miR‐223‐3p‐F | GGGGTGTCAGTTTGTCAAAT | 57 |
| miR‐223‐3p‐R | CTGGTGTCGTGGAGTCGG | |
| GAPDH‐F | GGGAAACTGTGGCGTGAT | 299 |
| GAPDH‐R | GAGTGGGTGTCGCTGTTGA | |
| U6‐F | CTCGCTTCGGCAGCACA | 94 |
| U6‐R | AACGCTTCACGAATTTGCGT |
2.5. ELISA
ELISA kits were used to detect the expressions of IL‐6, IL‐17, IL‐23, IL‐10, TGF‐β1, and FOXP3. The procedure was performed in accordance with the instructions of the kit.
2.6. Synthesis and transfection of miR‐223 mimics/NC and FOXP3 siRNA
Mimics/NCs were synthesized according to the sequence of hsa‐miR‐223‐3p (UGUCAGUUUGUCAAAUACCCCA), and transfected into cultured HCAECs cells. siRNA/NC was synthesized according to the sequence of FOXP3 and transfected into HCAECs cells by lipofection. Before transfection, and the cell confluency was 90% at the time of transfection. Dilute 5 µL Lipofectamine® RNAiMAX in 250 µL Opti‐MEM. The two were mixed and incubated at room temperature for 20 min. Place the cell plate in a 37°C incubator, change to fresh medium 4 h after transfection, and incubate for 48 h. Finally, the expression of the transgene was detected.
2.7. Cell co‐culture
Establish a cell co‐culture system. Divide the cells into nine groups: Control group (lower chamber: HCAECs cells, upper chamber: THP1 cells + healthy serum), siRNA group (lower chamber: HCAECs cells + siRNA, upper chamber: THP1 cells + healthy serum), siRNA‐NC group (lower chamber: HCAECs cells + siRNA‐NC, upper chamber: THP1 cells + healthy serum), KD group (lower chamber: HCAECs cells, upper chamber: THP1 cells + KD serum), KD + siRNA group (lower Chamber: HCAECs cells + siRNA, upper chamber: THP1 cells + KD serum), KD + siRNA‐NC group (lower chamber: HCAECs cells + siRNA‐NC, upper chamber: THP1 cells + KD serum), IVIG group (lower chamber: HCAECs cells, upper chamber: THP1 cells + IVIG serum), IVIG + siRNA group (lower chamber: HCAECs cells + siRNA, upper chamber: THP1 cells + IVIG serum), IVIG + siRNA‐NC group (lower chamber: HCAECs cells + siRNA‐NC, upper compartment: THP1 cells + IVIG serum). The coronary artery endothelial cells were collected, and the concentration of the cell suspension was adjusted with complete medium. Add transfected/untransfected FOXP3 siRNA and NC coronary artery endothelial cells in the lower chamber of the 6‐well plate Transwell, 2.6 mL/well. Collect THP1 cells, adjust the concentration of cell suspension with basal medium (without serum), add THP1 cells to the upper chamber, 1.2 mL/well. Afterwards, 0.3 mL of KD serum, IVIG treatment serum and healthy serum were added to the upper chamber, respectively. After 24 h of treatment, follow‐up testing.
2.8. MTT
Take out the cell culture plate, add 10 μL MTT solution to each well, and culture for 4 h. Add 150 uL DMSO solution. The absorbance of each well was measured at 490 nm.
2.9. Flow cytometry
Take 1 × 106 cells resuspended in medium, and centrifuge. Add Annexin V‐FITC and PI, and incubate at 4°C for 30 min. Three‐hundred microliters of PBS was added and flow cytometry was performed immediately. Analysis was performed using NovoExpress analysis software.
2.10. Western blot
Add 200 μL of lysate per 1 × 106 cells. Select stacking gel at 80 V for 40 min, separating gel at 120 V for 50 min, constant pressure 90 V for 50 min, and 5% nonfat milk powder at room temperature and block overnight at 4°C. Add primary antibodies (FOXP3 1:1000, caspase3 1:1000, Bcl2 1:1000, Bax: 1000, GAPDH 1:1000), and incubated for 1 h. The secondary antibody Goat anti‐Rabbit IgG (1:20000) was incubated at room temperature for 1 h. After adding ECL luminescent solution, color development was performed and the grayscale values of the relevant bands were read, and each group was repeated three times.
2.11. Data analysis
The data measured are expressed as mean ± standard deviation. One‐way ANOVA was used for comparison among multiple groups, and LSD test was used for pairwise comparison of means. Statistical analysis was performed using SPSS 17.0 software. The difference was statistically significant at p < .05.
3. RESULTS
3.1. Expression changes of miR‐223‐3p and FOXP3 in patients with Kawasaki disease
By collecting clinical samples, we found that compared with the control group, the expression of miR‐223‐3p and RORγt in the serum of acute KD patients was significantly upregulated, and the expressions of TGF‐β1 and FOXP3 were significantly downregulated. Compared with the KD group, the expression of miR‐223‐3p and RORγt in the serum of patients after IVIG treatment was significantly downregulated, and the expressions of TGF‐β1 and FOXP3 were significantly upregulated, Figure 1A. Compared with the control group, the proportion of Th17 cells in KD patients was significantly increased, the proportion of Treg cells was significantly decreased. The proportion of Th17 cells was significantly decreased and the proportion of Treg cells was significantly increased after IVIG treatment (Figure 1B). ELISA showed that (Figure 1C), the levels of IL‐6, IL‐17, and IL‐23 in the KD group were significantly higher than those in the control group, and the levels of IL‐10, TGF‐β1, and FOXP3 were significantly decreased. Compared with the KD group, the levels of IL‐6, IL‐17, and IL‐23 in the IVIG group were significantly decreased, and the levels of IL‐10, TGF‐β1, and FOXP3 were significantly increased. This result indicates that the serum of KD patients has high expression of miR‐223‐3p and low expression of FOXP3. However, after IVIG treatment, the expression of miR‐223‐3p was decreased, and the FOXP3 was increased.
Figure 1.

Expression changes of miR‐223‐3p and FOXP3 in patients with Kawasaki disease. (A) qRT‐PCR detection of serum miR‐223‐3p, TGF‐β1, RORγt, and FOXP3 expression; (B) Flow cytometry detection of serum Th17 and Treg cells. (C) The expressions of IL‐6, IL‐17, IL‐23, IL‐10, TGF‐β1, and FOXP3 in serum were detected by ELISA.
3.2. Effects of miR‐223‐3p expression on cell proliferation
Compared with the Normal group and the control group, the expression of miR‐223‐3p in the KD group was significantly increased, and the expression of FOXP3 was significantly decreased (Figure 2A,B). It is suggested that miR‐223‐3p may promote the progression of KD. Therefore, we further verified by constructing miR‐223 mimics/NC vector. The results showed that (Figure 2C–E), compared with the miR‐223‐3p NC group, the miR‐223‐3p mimics group increased the expression of miR‐223‐3p, inhibited cell proliferation, and promoted apoptosis. This result indicated that miR‐223‐3p could inhibit the activity of HCAECs cells.
Figure 2.

The effect of miR‐223‐3p expression on cell proliferation. (A) The expression of miR‐223‐3p was detected by qRT‐PCR; (B) The protein expression of FOXP3 was detected by western‐blot; (C) The expression of miR‐223‐3p was detected by qRT‐PCR; (D) MTT method was detected Cell proliferation; (E) Flow cytometry cell apoptosis rate.
3.3. The effect of FOXP3 interference on cell proliferation
As shown in Figure 3A,B, compared with the NC group, the miRNA and protein expressions of FOXP3 in the cells of the FOXP3‐shRNA1, FOXP3‐shRNA2, and FOXP3‐shRNA3 groups were significantly decreased. We selected the most interfering FOXP3‐shRNA1 for subsequent experiments. Compared with the control group, the siRNA group and the siRNA‐NC group, the proliferation ability of the KD group was significantly decreased, and the apoptosis was significantly increased. Compared with the KD + siRNA‐NC group, the cell proliferation ability of the KD + siRNA group was significantly decreased, and the apoptosis rate was significantly increased. Compared with the KD group, the proliferation ability of the cells in the IVIG group was significantly increased, and the apoptosis rate was significantly decreased. At the same time, compared with the IVIG + siRNA‐NC group, the proliferation ability of the cells in the IVIG+siRNA group was significantly decreased, and the apoptosis rate was significantly increased (Figure 3C–E). This result indicated that KD serum could inhibit the activity of HCAECs cells, and this situation was more obvious after interfering with the expression of FOXP3. The serum after IVIG treatment can increase cell viability.
Figure 3.

The effect of FOXP3 interference on cell proliferation. (A) qRT‐PCR detection of FOXP3 miRNA expression; (B) western‐blot detection of FOXP3 protein expression; (C) MTT detection of cell proliferation in each group; (D and E) Flow cytometry detection of cell apoptosis rate.
3.4. The effect of FOXP3 interference on the level of inflammation in cells
Compared with the control group, siRNA group and siRNA‐NC group, the expressions of FOXP3 and Bcl2 in the KD group were significantly downregulated, and the expressions of caspase3 and Bax were significantly upregulated. Compared with the KD + siRNA‐NC group, the results of the KD + siRNA group were consistent with the above. Compared with KD group, the expressions of FOXP3 and Bcl2 in IVIG group were significantly upregulated, and the expressions of caspase3 and Bax were significantly downregulated. Compared with IVIG + siRNA‐NC group, the expressions of FOXP3 and Bcl2 in IVIG + siRNA group were significantly downregulated, and the protein expressions of caspase3 and Bax were significantly upregulated, Figure 4A,B. At the same time, KD serum decreased the levels of TGF‐β1 and IL‐10, increased the levels of IL‐17, IL‐6, and IL‐23 (Figure 4C). The above results were more obvious when KD serum and siRNA were intervened together. In contrast, IVIG‐treated serum could raise the levels of TGF‐β1 and IL‐10 and decrease the levels of IL‐17, IL‐6, and IL‐23. In addition, miR‐223‐3p was significantly increased in the cells of the KD group compared to the control group. Compared with the KD + siRNA‐NC group, the KD+siRNA group also significantly increased miR‐223‐3p. The expression of miR‐223‐3p in cells was decreased in serum after IVIG treatment. These results indicated that miR‐223‐3p in the serum of KD patients may affect the apoptosis and inflammation levels of HCAECs by regulating the expression of FOXP3.
Figure 4.

The effect of FOXP3 interference on the level of inflammation in cells. (A and B) The protein expressions of FOXP3, caspase3, Bcl2, and Bax. (C) The expression of inflammatory cytokines IL‐6, IL‐17, IL‐23, IL‐10, and TGF‐β1 was detected by ELISA. (D) The expression of miR‐223‐3p.
4. DISCUSSION
KD is a frequent febrile multisystemic inflammatory disease in children. A sequence of infectious cellular events, both innate and adaptive immune cells and platelet activation, occur in the blood of KD patients. Its early diagnosis is critical for effective treatment, which including IVIG and, for those who do not respond, additional IVIG or other anti‐inflammatory agents, eliminating the inflammatory process and reducing the risk of coronary artery aneurysm (CAA) to approximately 5%–10%. 16 Impaired recovery from long‐term inflammatory damage leads to abnormal remodeling and severe coronary lesions in KD patients, according to previous studies. 17 Hyperactive platelets in KD result from inflammation and endothelial damage, and platelet hyperactivation increases the risk of coronary syndrome. 18 This study found that miR‐27b could target Smad7 and suppress the growth and immigration of HUVECs. 19 KD serum can increase the level of miR‐186 in HUVECs and induce apoptosis in HUVECs by targeting SMAD family member 6 (SMAD6) to activate mitogen‐activated protein kinase (MAPK), which may become a therapeutic target for KD. 20 Therefore, mining miRNAs related to HUVECs apoptosis is a direction of KD targeted therapy. It found that the level of miR‐223 was increased during LCWE‐induced KD vasculitis, but miR‐223 appeared to reduce inflammation in vascular tissue by inhibiting NLRP3 activation and IL‐1β production. 21 It has also been found that the co‐culture of activated platelets and endothelial cells in KD patients will lead to the upregulation of miR‐223 expression in endothelial cells, and the upregulated miR‐223 will reduce the adhesion of leukocytes to endothelial cells. 22 In another study, it was found that in KD patients, blood cell‐derived miR‐223 in vascular endothelial cells was elevated, and the increased miR‐223 may be involved in the vascular injury of KD as a new endocrine genetic signal. 13 Therefore, there are currently inconsistent reports on the role of miR‐223 on endothelial cells. Consistent with our results, the expression of miR‐223 was increased in KD patients. The effect of miR‐223 on endothelial cells may be inconsistent due to the different research methods. Our results found that the expression of miR‐223‐3p was significantly upregulated in serum of KD during acute phase. Inflammatory blood cells derived from bone marrow hematopoietic cells can secrete miR‐223 into circulating serum, and miR‐223 secreted by blood cells can act as a new endocrine signal to enter vascular smooth muscle cells (VSMCs) and regulate its function and atherosclerosis through its target gene. 23
Studies have shown that the proportion of Th17 (helper type 17) cells in the acute phase of KD is higher, and the expression of cytokines IL‐17, IL‐6, IL‐23 is increased, and the study also found that the proportion of Th17 cells in IVIG‐resistant patients was higher than that in IVIG response patient. 24 These studies illustrate the pathological importance of T cells in children with acute KD. In this study, it was found that the proportion of Th17 cells in the serum of KD patients with acute was significantly increased, and the proportion of Treg cells was significantly decreased. Traditional Treg cells produce anti‐inflammatory cytokines such as IL‐10, transforming growth factor TGF‐β and IL‐35. The levels of IL‐6, TNF‐α, and IFN‐γ were significantly increased in the acute phase of KD, whereas the levels of IL‐6 and IFN‐γ decreased after IVIG treatment. 25 In this study, the levels of IL‐6, IL‐17, and IL‐23 were increased, and the levels of IL‐10, TGF‐β1, and FOXP3 were decreased in patients with acute KD. The opposite results were obtained in the serum of patients after IVIG treatment. FOXP3 exerts immunomodulatory effects through various mechanisms including secretion of IL‐10 and TGF‐β. 26 Through clinical data, it was found that the expression of FOXP3 was downregulated in the serum of acute patients. At the same time, the expression of FOXP3 was also downregulated in HCAECs cells containing KD serum. In addition, overexpression of miR‐223‐3p was also found to promote cell apoptosis. This is consistent with the result that highly expressed miR‐223‐3p in KD serum promotes apoptosis. miR‐223‐3p may regulate the apoptosis of coronary endothelial cells by regulating FOXP3, and then participate in the progression of KD.
Inflammatory cytokines are released by a variety of cells in KD. These inflammatory factors are attributed to the activation of apoptosis. 27 In addition, KD involves the activation of innate and adaptive immunity, leading to the release of cytokines and the creation of an inflammatory environment. Studies have found that cytokines released by THP1 play an important role in acute KD vascular endothelial injury, THP1 cell line has been widely used as an in vitro model of human monocytes and macrophages for the study of the mechanism of inflammatory diseases. 28 , 29 , 30 The THP1 cell line is essential for inducing inflammatory conditions in KD. We established a co‐culture system between HCAECs cells transfected with FOXP3 siRNA and THP1 cells added with three serum. The results showed that both high expression of miR‐223‐3p and low expression of FOXP3 in KD serum increased cell apoptosis. Meanwhile, the protein expressions of caspase3 and Bax were significantly upregulated. In addition, the highly expressed miR‐223‐3p in KD serum decreased the level of FOXP3. It is suggested that miR‐223‐3p may play a role in KD by regulating FOXP3.
5. CONCLUSION
In conclusion, this study collected serum samples from acute KD, after IVIG treatment, and healthy controls. It was verified that KD serum has high level of miR‐223‐3p and low level of FOXP3. A co‐culture system was established with HCAECs cells and THP1 cells treated with three serum samples. It was verified that serum miR‐223‐3p in KD patients may affect cell proliferation, apoptosis, and the expression of inflammatory cytokines by regulating FOXP3.
AUTHOR CONTRIBUTIONS
Ronghao Zheng: Review and editing (equal). Jing Xie: Review and editing (equal). Weijie Li: Formal analysis. Jianping Shang: Formal analysis. Zuliang Shi: Software. Songbai Zhu: Software. Lin Gui: Methodology. Li Huang: Methodology. Lan Shu: Conceptualization. Donglei Liu: Conceptualization. Xiaofen Huang: Conceptualization. Yi Gong: Review and editing. Xiaohui Li: Review and editing. Wanxia Chai: Review and editing. Xiaolin Wu: Writing—original draft (lead). Jing Yue: Writing—original draft (lead).
CONFLICT OF INTEREST STATEMENT
The authors declare no conflict of interest.
ETHICS STATEMENT
This study was obtained permission from the Medical Ethics Committee of Hubei Provincial Maternal and Child Health Hospital (2020IECXM029). Before participating in this study, notified consent was obtained from each patient.
ACKNOWLEDGMENTS
This study was supported by Health Commission of Hubei Province scientific research project (WJ2021M186).
Zheng R, Xie J, Li W, et al. MiR‐223‐3p affects the proliferation and apoptosis of HCAECs in Kawasaki disease by regulating the expression of FOXP3. Immun Inflamm Dis. 2023;11:e939. 10.1002/iid3.939
Ronghao Zheng and Jing Xie contributed equally to this study.
Contributor Information
Xiaolin Wu, Email: wuxiaolin18@126.com.
Jing Yue, Email: elvia619@163.com.
DATA AVAILABILITY STATEMENT
The data used to support the findings of this study are included within the article.
REFERENCES
- 1. Newburger JW, Takahashi M, Burns JC. Kawasaki disease. JACC. 2016;67(14):1738‐1749. [DOI] [PubMed] [Google Scholar]
- 2. Chen KYH, Curtis N, Dahdah N, Kowalski R, Cheung M, Burgner DP. Kawasaki disease and cardiovascular risk: a comprehensive review of subclinical vascular changes in the longer term. Acta Paediatr. 2016;105(7):752‐761. [DOI] [PubMed] [Google Scholar]
- 3. Butters C, Curtis N, Burgner DP. Kawasaki disease fact check: myths, misconceptions and mysteries. J Paediatr Child Health. 2020;56(9):1343‐1345. [DOI] [PubMed] [Google Scholar]
- 4. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long‐term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927‐e999. [DOI] [PubMed] [Google Scholar]
- 5. Yu JJ. Use of corticosteroids during acute phase of Kawasaki disease. World J Clin Pediatr. 2015;4(4):135‐142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Lo MS, Newburger JW. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis. 2018;21(1):64‐69. [DOI] [PubMed] [Google Scholar]
- 7. Ohnishi Y, Mori K, Inoue M, Satake N, Yano M. A case of Kawasaki disease presenting as sigmoid colitis. J Med Ultrasound. 2018;45(2):381‐384. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Wang L, Zhang S, Ma J, et al. Kawasaki disease‐management strategies given symptoms overlap to COVID‐19: a review. J Nepal Med Assoc. 2021;59(236):417‐424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Zhao Z, Sun W, Guo Z, Zhang J, Yu H, Liu B. Mechanisms of lncRNA/microRNA interactions in angiogenesis. Life Sci. 2020;254:116900. [DOI] [PubMed] [Google Scholar]
- 10. Zhang N, Hu X, Du Y, Du J. The role of miRNAs in colorectal cancer progression and chemoradiotherapy. Biomed Pharmacother. 2021;134:111099. [DOI] [PubMed] [Google Scholar]
- 11. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303(5654):83‐86. [DOI] [PubMed] [Google Scholar]
- 12. Chen Y, Ding YY, Ren Y, et al. Identification of differentially expressed microRNAs in acute Kawasaki disease. Mol Med Rep. 2018;17(1):932‐938. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Chu M, Wu R, Qin S, et al. Bone marrow‐derived MicroRNA‐223 works as an endocrine genetic signal in vascular endothelial cells and participates in vascular injury from Kawasaki disease. J Am Heart Assoc. 2017;6(2):e004878. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Chang L, Yang HW, Lin TY, Yang KD. Perspective of immunopathogenesis and immunotherapies for Kawasaki disease. Front Pediatr. 2021;9:697632. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Deng G, Song X, Fujimoto S, Piccirillo CA, Nagai Y, Greene MI. Foxp3 post‐translational modifications and treg suppressive activity. Front Immunol. 2019;10:2486. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Wright VJ, Herberg JA, Kaforou M, et al. Diagnosis of Kawasaki disease using a minimal whole‐blood gene expression signature. JAMA Pediatr. 2018;172(10):e182293. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Zhang Y, Wang Y, Zhang L, et al. Reduced platelet miR‐223 induction in Kawasaki disease leads to severe coronary artery pathology through a miR‐223/PDGFRβ vascular smooth muscle cell axis. Circ Res. 2020;127(7):855‐873. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Nagalla S, Shaw C, Kong X, et al. Platelet microRNA‐mRNA coexpression profiles correlate with platelet reactivity. Blood. 2011;117(19):5189‐5197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Rong X, Ge D, Shen D, et al. miR‐27b suppresses endothelial cell proliferation and migration by targeting Smad7 in kawasaki disease. Cell Physiol Biochem. 2018;48(4):1804‐1814. [DOI] [PubMed] [Google Scholar]
- 20. Wu R, Shen D, Sohun H, et al. miR‑186, a serum microRNA, induces endothelial cell apoptosis by targeting SMAD6 in Kawasaki disease. Int J Mol Med. 2018;41(4):1899‐1908. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Maruyama D, Kocatürk B, Lee Y, et al. MicroRNA‐223 regulates the development of cardiovascular lesions in LCWE‐induced murine Kawasaki disease vasculitis by repressing the NLRP3 inflammasome. Front Pediatr. 2021;9:662953. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Guo M, Fan S, Chen Q, et al. Platelet‐derived microRNA‐223 attenuates TNF‐α induced monocytes adhesion to arterial endothelium by targeting ICAM‐1 in Kawasaki disease. Front Immunol. 2022;13:922868. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Shan Z, Qin S, Li W, et al. An endocrine genetic signal between blood cells and vascular smooth muscle cells. JACC. 2015;65(23):2526‐2537. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Jia S, Li C, Wang G, Yang J, Zu Y. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin Exp Immunol. 2010;162(1):131‐137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Wang Y, Wang W, Gong F, et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheumatol. 2013;65(3):805‐814. [DOI] [PubMed] [Google Scholar]
- 26. Pacheco‐Gonzalez RM, Avila C, Dávila I, et al. Analysis of FOXP3 gene in children with allergy and autoimmune diseases. Allergol Immunopathol. 2016;44(1):32‐40. [DOI] [PubMed] [Google Scholar]
- 27. Jia C, Zhang J, Chen H, et al. Endothelial cell pyroptosis plays an important role in Kawasaki disease via HMGB1/RAGE/cathespin B signaling pathway and NLRP3 inflammasome activation. Cell Death Dis. 2019;10(10):778. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Furukawa S, Matsubara T, Jujoh K, et al. Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol. 1988;48(2):247‐251. [DOI] [PubMed] [Google Scholar]
- 29. Ichiyama T, Yoshitomi T, Nishikawa M, et al. NF‐κB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol. 2001;99(3):373‐377. [DOI] [PubMed] [Google Scholar]
- 30. Chanput W, Mes JJ, Wichers HJ. THP‐1 cell line: an in vitro cell model for immune modulation approach. Int Immunopharmacol. 2014;23(1):37‐45. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data used to support the findings of this study are included within the article.
